Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

IMMUNE, DERMAL AND INFECTIOUS DISEASES

figure with microscope of cells, fumes

Dermal Diseases

Outcomes

Outcomes are events, occurrences, or conditions that indicate progress in achieving the purpose of the program. Outcomes reflect the results of a program activity compared with its intended purpose; or, outcomes may answer the question "Will these resources result in success or contribute to the success of what we want to accomplish?"

Outcomes can be viewed from two different perspectives--ultimate and intermediate. For an occupational safety and health research program like the NIOSH Immune, Dermal & Infectious Diseases Program, ultimate outcomes are reductions in a particular type of worker injury or illness. Injuries and illnesses have complex causes, and any effect of program activities on rates can take years to be seen. Therefore, outcomes are often measured on an intermediate timeframe. Intermediate outcomes are necessary steps that lead to ultimate outcomes--for example, reductions in the risk of a particular type of injury or illness. For occupational safety and health research programs, achieving intermediate risk reductions is as important as achieving the ultimate outcome of decreasing injury and illness incidence rates.


Strategic Goal 1

Provide research in identification of OCD hazards and assessment of workplace exposures and explore effective strategies of exposure prevention and control.

The ultimate goal is to translate research findings into recommendations and solutions of workplace practice to guide the OSH community, consisting of employers and employees in affected industries, policy makers, health care providers, and researchers, in the collective effort of reducing morbidity among our nation’s workers.

Performance Measures:

The achievement of missions in Strategic Goal 1 will be measured, in sequence, by: (1) production of scientifically based NIOSH recommendations and guidelines for skin exposure assessments and intervention strategies; (2) acceptance and use of NIOSH products by stakeholders; (3) reduction of skin irritants and allergens in the workplace and of exposures to these substances; and (4) reduction in the incidence and prevalence of OCD. Measures (1) and (2) shall demonstrate the effectiveness of NIOSH efforts increasing knowledge among stakeholders and promoting implementation of feasible interventions by the affected industries. The progression of and rehabilitation from OCD of delayed or chronic natures vary among individuals and may not serve as an immediate measure to reflect the effectiveness of interventions. Instead, in Measure (3) the reduction of workplace exposures to dermatitic agents will be used as an interim indicator. Measure (4) realizes the long-term impacts of the NIOSH program on reducing the illness, as formulated in the Healthy People 2010 Objectives.


Strategic Goal 2

Prevent systemic disease from occupational skin exposure to chemicals by translation of research results and recommendations into workplace practice.

Performance Measures:

The achievement of missions in Strategic Goal 2 will be measured, in sequence, by: (1) producing scientific publications containing critical information and scientifically-based NIOSH recommendations and guidelines for skin exposure assessments and intervention strategies; (2) acceptance and use of NIOSH products by stakeholders; (3) identification of systemic toxics by the skin route in the workplace and reduction of over-exposures to these substances; and (4) reduction in the incidence and prevalence of systemic effects attributable to skin exposures. Measures (1) and (2) will demonstrate the effectiveness of NIOSH efforts to increase knowledge among stakeholders and to promote implementation of feasible interventions by the affected industries. The progression of systemic toxicity, especially after chronic exposure, often includes long delays, so measures of ill-health may not serve as a timely measure of the effectiveness of interventions. Instead, in Measure (3) the identification of previously unknown hazards and the reduction of workplace exposures to known systemic toxics by the skin route will be used as an interim indicator. Measure (4) realizes the long-term impacts of the NIOSH program on reducing illness.


Strategic Goal 3

Prevent occupational skin cancer by translation of research results and recommendations into workplace practice.

Performance Measures:

The achievement of missions in Strategic Goal 3 will be measured, in sequence, by: (1) production of scientific publications containing critical information and production of scientifically based NIOSH recommendations and plain-language guidelines for reducing exposures known to cause occupational skin cancer; (2) determination whether there is an increased risk of occupational skin cancer in at least one under-studied work situation that is suspected of being hazardous; (3) successful demonstration of a practical prevention program as measured by a reduction in over-exposures related to occupational skin cancer in at least one intervention study conducted in a known hazardous work situation; and (4) acceptance and adaptation of NIOSH products and programs by stakeholders.

 

 
Contact Us:
  • Page last reviewed: December 18, 2012
  • Page last updated: December 18, 2012
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO